Inside CKD: a microsimulation modelling study projects the clinical and economic burden of chronic kidney disease in Hungary
<i>Inside CKD</i> demonstrates that the future burden of CKD in Hungary will be substantial unless current management strategies change. The high prevalence of undiagnosed CKD and associated cardiorenal complications highlight the urgent need for policy interventions focused on early diagnosis and timely intervention to mitigate the future burden of CKD.
Authors
- Claudia Cabrera (ORCID: https://orcid.org/0000-0003-2778-1604)
- Salvatore Barone
- Erzsébet Ladányi
- Luca Adél Halmai (ORCID: https://orcid.org/0000-0002-8389-4796)
- István Wittmann (ORCID: https://orcid.org/0000-0001-5163-5733)
- Boglárka Laczy
- Juan José García Sánchez (ORCID: https://orcid.org/0000-0001-6546-7769)
- Lise Retat (ORCID: https://orcid.org/0000-0002-6689-3599)
- Laura Webber (ORCID: https://orcid.org/0000-0002-8976-1919)
- Lilla Szabó
Institutions
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (United States) (US)
- University of Pecs (HU)
Publication Details
- Journal
- Frontiers in Nephrology
- Published
- 2024-10-18
- DOI
- https://doi.org/10.3389/fneph.2024.1458607
- Citations
- 2
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.68
Funders
- AstraZeneca